A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Gastrointestinal Stromal Tumors, sponsored by Bayer. Completed at 57 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing regorafenib in Gastrointestinal Stromal Tumors — 1 open to participants now, 3 under way, none of them phase 3. regorafenib · Gastrointestinal Stromal Tumors.
Among the 10 studies testing regorafenib in Gastrointestinal Stromal Tumors, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 2nd registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →1 of the 10 studies testing regorafenib in Gastrointestinal Stromal Tumors is open now, in 1 country. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+
By country, each count listing its studies:
regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 199 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 28 across the 10 interventional studies. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 7 studies filed under Gastrointestinal Stromal Tumors — fewer than ten, so there is no comparison to draw.
1 of the studies testing regorafenib in Gastrointestinal Stromal Tumors that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05366816University of MiamictDNA-Guided Sunitinib And Regorafenib Therapy for GIST | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing regorafenib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.
The study is composed of 3 periods: A Screening Period, a Treatment Period, and a Survival Follow up Period.
Subjects randomized to be treated with regorafenib will receive 160 mg po od for 3 weeks of every 4 week (28 day) cycle (ie, 3 weeks on/1 week off). In addition subjects will receive best supportive care which excludes any disease specific anti cancer therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgery.
Tumor assessment will be every 4 weeks for the first 3 months, every 6 weeks for the next 3 months (through month 6), and every 8 weeks until the end of treatment, or more frequently if clinically indicated. Tumor assessments include CT or MRI and will be performed until tumor progression is seen in a central radiology review.
Subjects receiving placebo who experience disease progression may be offered active treatment.
Subjects who experience progression during regorafenib treatment may continue open label treatment.
All subjects will enter the Survival Follow-up Period upon discontinuation of randomized study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(ECOG) Performance Status of 0 or 1.
Recovery to v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure-related toxicity (except alopecia and anemia).
Exclusion Criteria:
Arterial thrombotic or embolic events such as cerebrovascular accident (including ), or pulmonary embolism within the 6 months before start of study drug or venous thrombotic events such as deep vein thrombosis within the 3 months before start of study drug.
Symptomatic brain or meningeal tumors.
Non-healing wound, ulcer, or bone fracture.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Drug: Regorafenib (Stivarga, BAY73-4506) · Drug: Best supportive care
Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
Drug: Placebo · Drug: Best supportive care
160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
once daily (od), 3 weeks on/1 week off. Route of administration: oral
Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
Progression-free Survival
Progression-free Survival (PFS) was defined as the time from date of randomization to radiological disease progression or death due to any cause, whichever occurs first. PFS was based on central radiological assessment using modified RECIST (Response Evaluation Criteria in Solid Tumors) v.1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.
Time frame: From randomization of the first subject until approximately 144 progression-free survival events had occurred (study duration approximately one year)
Overall Survival
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Median OS was not observed at the time of PFS analysis and first analysis of OS, therefore only the proportion of death events was reported in the results posting system. This approach was maintained for the subsequent updates in the results posting system.
Time frame: From randomization of the first subject until date of database cutoff (08 Jun 2015)
Time to Progression (TTP)
Time to progression (TTP) was defined as the time from date of randomization to disease progression (based on central radiological assessment using modified RECIST \[Response Evaluation Criteria in Solid Tumors\] v.1.1). Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.
Time frame: From randomization of the first subject until until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Tumor Response
Tumor Response of a subject was defined as the best tumor response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\], Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], Stable Disease \[SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], or Progressive Disease \[PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.\]) observed during the trial period and assessed according to RECIST v1.1 criteria. Results are based on central evaluation.
Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Objective Response Rate
Objective response rate was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Results are based on central evaluation.
Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year.
Disease Control Rate (DCR)
Disease Control Rate (DCR) was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or Stable Disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST v1.1 criteria. SD had to be maintained for at least 12 weeks from the first demonstration of that rating. Results are based on central evaluation.
Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Duration of Response (DOR)
Duration of Response was defined as the time from date of first response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\] or Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\]) to the date when Progressive Disease (PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.) is first documented, or to the date of death, whichever occurs first, according to RECIST v1.1. Subjects still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. Duration of response defined for responders only, i.e CR or PR. Results are based on central evaluation.
Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
A total of 240 participants with metastatic and/or unresectable GIST whose disease had progressed despite prior treatments with at least imatinib and sunitinib were screened; 199 were randomized. Patients must have shown objective disease progression or intolerance to imatinib, as well as disease progression while on sunitinib treatment.
| Milestone | Regorafenib (Stivarga, BAY73-4506) | Placebo First, Then Option of Open Label Regorafenib Treatment |
|---|---|---|
| Started | 133 | 66 |
| Participants received treatment | 132 | 66 |
| Completed | 91 | 58 |
| Not completed | 42 | 8 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Adverse event | 9 | 4 |
| Withdrew: Progressive disease | 23 | 3 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Non compliance with study drug | 2 | 0 |
| Withdrew: Receive no study drug | 1 | 0 |
| Milestone | Regorafenib (Stivarga, BAY73-4506) | Placebo First, Then Option of Open Label Regorafenib Treatment |
|---|---|---|
| Started | 91 | 58 |
| Completed | 0 | 0 |
| Not completed | 91 | 58 |
| Withdrew: Death | 6 | 5 |
| Withdrew: Withdrawal by subject | 6 | 11 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Adverse event | 14 | 8 |
| Withdrew: Progressive disease | 59 | 32 |
| Withdrew: Transferred to rollover study | 1 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Switching to other therapy | 2 | 1 |
| Milestone | Regorafenib (Stivarga, BAY73-4506) | Placebo First, Then Option of Open Label Regorafenib Treatment |
|---|---|---|
| Started | 118 | 52 |
| Completed | 97 | 37 |
| Not completed | 21 | 15 |
| Withdrew: Death | 11 | 7 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Not analyzed after cutoff 08jun2015 | 3 | 4 |
| Withdrew: No follow-up | 1 | 1 |
| Withdrew: Progressive disease | 1 | 0 |
| Milestone | Regorafenib (Stivarga, BAY73-4506) | Placebo First, Then Option of Open Label Regorafenib Treatment |
|---|---|---|
| Started | 100 | 39 |
| Completed | 85 | 33 |
| Not completed | 15 | 6 |
| Withdrew: Not analyzed after cutoff 08jun2015 | 15 | 6 |
Progression-free Survival (PFS) was defined as the time from date of randomization to radiological disease progression or death due to any cause, whichever occurs first. PFS was based on central radiological assessment using modified RECIST (Response Evaluation Criteria in Solid Tumors) v.1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.
| Days | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Progression-free Survival | 147 (122 to 173) | 28 (28 to 32) |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Median OS was not observed at the time of PFS analysis and first analysis of OS, therefore only the proportion of death events was reported in the results posting system. This approach was maintained for the subsequent updates in the results posting system.
| Percentage of patients with death | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Overall Survival | 82.0 | 80.3 |
Time to progression (TTP) was defined as the time from date of randomization to disease progression (based on central radiological assessment using modified RECIST \[Response Evaluation Criteria in Solid Tumors\] v.1.1). Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.
| Days | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Time to Progression (TTP) | 165 (125 to 174) | 28 (28 to 34) |
Tumor Response of a subject was defined as the best tumor response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\], Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], Stable Disease \[SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], or Progressive Disease \[PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.\]) observed during the trial period and assessed according to RECIST v1.1 criteria. Results are based on central evaluation.
| Percentage of Participants | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Complete Response (CR) | 0 (0 to 0) | 0 (0 to 0) |
| Partial Response (PR) | 4.5 (1.7 to 9.6) | 1.5 (0 to 8.2) |
| Stable Disease (SD) | 71.4 (63.0 to 78.9) | 33.3 (22.2 to 46.0) |
| Progressive Disease (PD) | 21.1 (14.5 to 29.0) | 63.6 (50.9 to 75.1) |
| Not Assessable | 3.0 (0.8 to 7.5) | 1.5 (0 to 8.2) |
Objective response rate was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Results are based on central evaluation.
| Percentage of Participants | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Objective Response Rate | 4.5 (1.7 to 9.6) | 1.5 (0.0 to 8.2) |
Disease Control Rate (DCR) was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or Stable Disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST v1.1 criteria. SD had to be maintained for at least 12 weeks from the first demonstration of that rating. Results are based on central evaluation.
| Percentage of Participants | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Disease Control Rate (DCR) | 52.6 (43.8 to 61.3) | 9.1 (3.4 to 18.7) |
Duration of Response was defined as the time from date of first response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\] or Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\]) to the date when Progressive Disease (PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.) is first documented, or to the date of death, whichever occurs first, according to RECIST v1.1. Subjects still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. Duration of response defined for responders only, i.e CR or PR. Results are based on central evaluation.
| Days | Regorafenib (Stivarga, BAY73-4506) | Placebo |
|---|---|---|
| Duration of Response (DOR) | 99 (42 to NA) | 30 (NA to NA) |
Collected over From first administration of treatment till 30 days after last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Regorafenib (Double Blind Only) | 40/41 (97.6%) | 23/41 (56.1%) | 40/41 (97.6%) |
| Placebo (Double Blind Only) | 7/8 (87.5%) | 8/8 (100%) | 7/8 (87.5%) |
| Placebo, Open Label Only (Switch to Regorafenib) | 47/58 (81%) | 31/58 (53.4%) | 58/58 (100%) |
| Treated With Regorafenib at Any Time | 155/190 (81.6%) | 103/190 (54.2%) | 189/190 (99.5%) |
| Treated With Regorafenib for > 1 Year | 48/75 (64%) | 39/75 (52%) | 75/75 (100%) |
| Event | Regorafenib (Double Blind Only) | Placebo (Double Blind Only) | Placebo, Open Label Only (Switch to Regorafenib) | Treated With Regorafenib at Any Time | Treated With Regorafenib for > 1 Year |
|---|---|---|---|---|---|
| Death NOSGeneral disorders | 1/41 | 2/8 | 1/58 | 3/190 | 2/75 |
| NauseaGastrointestinal disorders | 0/41 | 1/8 | 1/58 | 2/190 | 1/75 |
| FatigueGeneral disorders | 2/41 | 1/8 | 2/58 | 5/190 | 2/75 |
| Non-cardiac chest painGeneral disorders | 0/41 | 1/8 | 0/58 | 0/190 | 0/75 |
| General disorders and administration site conditions - OtherGeneral disorders | 1/41 | 1/8 | 2/58 | 5/190 | 3/75 |
| Hepatobiliary disorders - OtherHepatobiliary disorders | 0/41 | 1/8 | 1/58 | 2/190 | 1/75 |
| DehydrationMetabolism and nutrition disorders | 0/41 | 1/8 | 0/58 | 3/190 | 3/75 |
| HyperglycemiaMetabolism and nutrition disorders | 0/41 | 1/8 | 0/58 | 0/190 | 0/75 |
| ManiaPsychiatric disorders | 0/41 | 1/8 | 0/58 | 0/190 | 0/75 |
| Abdominal painGastrointestinal disorders | 5/41 | 0/8 | 2/58 | 9/190 | 1/75 |
| Event | Regorafenib (Double Blind Only) | Placebo (Double Blind Only) | Placebo, Open Label Only (Switch to Regorafenib) | Treated With Regorafenib at Any Time | Treated With Regorafenib for > 1 Year |
|---|---|---|---|---|---|
| HypertensionVascular disorders | 18/41 | 3/8 | 37/58 | 124/190 | 62/75 |
| Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders | 17/41 | 1/8 | 39/58 | 126/190 | 58/75 |
| DiarrheaGastrointestinal disorders | 15/41 | 1/8 | 24/58 | 96/190 | 53/75 |
| ConstipationGastrointestinal disorders | 10/41 | 5/8 | 16/58 | 63/190 | 28/75 |
| FatigueGeneral disorders | 18/41 | 3/8 | 32/58 | 104/190 | 46/75 |
| Mucositis oralGastrointestinal disorders | 14/41 | 2/8 | 21/58 | 81/190 | 38/75 |
| AlopeciaSkin and subcutaneous tissue disorders | 7/41 | 0/8 | 21/58 | 62/190 | 33/75 |
| NauseaGastrointestinal disorders | 9/41 | 3/8 | 18/58 | 61/190 | 32/75 |
| AnorexiaMetabolism and nutrition disorders | 15/41 | 3/8 | 20/58 | 77/190 | 32/75 |
| PainGeneral disorders | 5/41 | 1/8 | 19/58 | 55/190 | 29/75 |
| Age, Continuous(Years) | Regorafenib (Stivarga, BAY73-4506) | Placebo | Total |
|---|---|---|---|
| Mean | 58.2 ± 12.5 | 58.1 ± 13.9 | 58.2 ± 12.9 |
| Sex: Female, Male(Participants) | Regorafenib (Stivarga, BAY73-4506) | Placebo | Total |
|---|---|---|---|
| Female | 48 | 24 | 72 |
| Male | 85 | 42 | 127 |
| ECOG Performance Status (PS)](Participants) | Regorafenib (Stivarga, BAY73-4506) | Placebo | Total |
|---|---|---|---|
| PS 0 | 73 | 37 | 110 |
| PS 1 | 60 | 29 | 89 |
| PS 2 | 0 | 0 | 0 |
| Missing | 0 | 0 | 0 |
| Prior anti-cancer drug group(Participants) | Regorafenib (Stivarga, BAY73-4506) | Placebo | Total |
|---|---|---|---|
| 3rd line | 74 | 39 | 113 |
| 4th line and beyond | 59 | 27 | 86 |
Ran from Jan 2011 to primary completion in Jan 2012, 12 months.
Results were first posted in Oct 2013, 1 year 8 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Regorafenib
Gastrointestinal Stromal Tumors →